The American Medical Association Current Procedural Terminology Panel approved Vermillion Inc.'s (Nasdaq: VRML) Category 1 CPT code application for its OVA1 test to differentiate benign versus malignant ovarian masses. The stock price more than doubled by jumping $1.67 to close at $3.00.